DUBLIN, Nov. 21, 2019 /PRNewswire/ -- The "Global Cardiovascular Partnering 2014-2019: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
Global Cardiovascular Partnering 2014 to 2019 provides the full collection of Cardiovascular disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Cardiovascular disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Cardiovascular deals.
The report presents financial deal terms values for Cardiovascular deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Cardiovascular technologies and products.
Report Scope
The report includes deals for the following indications: Abdominal aortic aneurysm, Angina, Arrhythmia, Atrial fibrillation, Long QT syndrome, Supraventricular Tachycardia, Ventricular fibrillation, Ventricular tachycardia, Atherosclerosis, Breathlessness, Cardiogenic shock, Cardiomyopathy (heart muscle disease), Chest pain, Congenital heart disease, Congestive heart failure, Coronary artery disease, Ductus arteriosus, Fatigue, Hypercholesterolemia, Hypertension, Intermittent claudication, Ischemic heart disease, Limb ischemia, Marfan's Syndrome, Myocardial Infarction, Oedema (excess fluid), Palpitations, Peripheral arterial disease, Thrombus (blood clot), Valvular heart disease, Aortic stenosis, Restenosis, Varicose veins, plus other cardiovascular indications.
In Global Cardiovascular Partnering 2014-2019: Deal trends, players and financials, the available deals are listed by:
Analyzing actual contract agreements allows assessment of the following:
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Cardiovascular dealmaking
2.1. Introduction
2.2. Cardiovascular partnering over the years
2.3. Cardiovascular partnering by deal type
2.4. Cardiovascular partnering by industry sector
2.5. Cardiovascular partnering by stage of development
2.6. Cardiovascular partnering by technology type
2.7. Cardiovascular partnering by therapeutic indication
Chapter 3 - Financial deal terms for Cardiovascular partnering
3.1. Introduction
3.2. Disclosed financials terms for Cardiovascular partnering
3.3. Cardiovascular partnering headline values
3.4. Cardiovascular deal upfront payments
3.5. Cardiovascular deal milestone payments
3.6. Cardiovascular royalty rates
Chapter 4 - Leading Cardiovascular deals and dealmakers
4.1. Introduction
4.2. Most active in Cardiovascular partnering
4.3. List of most active dealmakers in Cardiovascular
4.4. Top Cardiovascular deals by value
Chapter 5 - Cardiovascular contract document directory
5.1. Introduction
5.2. Cardiovascular partnering deals where contract document available
Chapter 6 - Cardiovascular dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Cardiovascular therapeutic target
Appendices
Appendix 1 - Directory of Cardiovascular deals by company A-Z 2014 to 2019
Appendix 2 - Directory of Cardiovascular deals by deal type 2014 to 2019
Appendix 3 - Directory of Cardiovascular deals by stage of development 2014 to 2019
Appendix 4 - Directory of Cardiovascular deals by technology type 2014 to 2019
For more information about this report visit https://www.researchandmarkets.com/r/ubpocm
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
These press releases may also interest you
|